Orasure Technologies Stock Earnings Reports

OraSure reported Q1 2026 revenue of $27.9 million (up 4% sequentially) with diagnostic revenue of $16.9 million and Sample Management revenue of $9.1 million. Gross margins expanded (GAAP 42.3%, non-GAAP 43.4%) driven by insourcing production and factory absorption. Management highlighted progress on international “near-shoring” in Africa and integration of BioMedomics and SickleSCAN distribution. Key near-term commercial catalysts are two midyear product launches: an OTC rapid molecular self-test for CT/NG (Sherlock platform) and the Colli-Pee at‑home urine collection device for STIs; both FDA submissions are in review with anticipated midyear clearances and revenue ramp in H2. Q2 guidance: revenue $27M–$30M, gross margin similar to Q1, operating expense high‑$20M (ex. stock comp) with expenses expected to decline to mid‑$20M in Q3 as non‑run-rate items wind down. Financial position: $177M cash, zero debt, $5M of share repurchases in Q1 (1.8M shares), $20M returned over 4 quarters. Q1 operating cash flow was negative $14M; management expects to return to breakeven operating cash flow in 2027. Increased R&D spending in Q1 reflects launch and production readiness activities; R&D is expected to taper in Q2–Q3. Overall strategy focuses on decentralizing diagnostics, leveraging manufacturing capacity for margin expansion, targeted R&D, and M&A/partnerships to accelerate profitable growth.